Founded in North Carolina, Ridge Diagnostics is a neurodiagnostic company with a core mission to revolutionize the diagnosis and treatment of Major Depressive Disorder (MDD) through innovative blood tests. Utilizing its proprietary Human Biomarker Library and Biomarker Hyper-Map™ technology platform, the company has developed multi-variant biological marker assays and diagnostic algorithms. These advancements enable more precise and effective management of depression, addressing a significant need in mental health care.
Ridge Diagnostics operates a CLIA-certified laboratory, ensuring high standards in clinical testing. The company has garnered attention from notable investors and medical professionals who recognize the potential impact of its technology. Key achievements include the successful development and commercialization of its first-in-class blood test for MDD. Ridge Diagnostics' work has significantly advanced the field of neurodiagnostics, offering new hope for patients and clinicians in the battle against depression.
Quick Facts
When was Ridge Diagnostics' last funding round?
Ridge Diagnostics' most recent funding round was for $250k (USD) in April 2013.
How much disclosed funding has Ridge Diagnostics raised?
As of Apr 18, 2013, Ridge Diagnostics has disclosed funding of $827k (USD).
